Drug development for severe asthma: what are the metrics?
about
The Impact of the Sanctions Made Against Iran on Availability to Asthma Medicines in Tehran.Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling.Emerging concepts in smooth muscle contributions to airway structure and function: implications for health and disease.An Official American Thoracic Society Research Statement: Current Challenges Facing Research and Therapeutic Advances in Airway Remodeling.PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.
P2860
Drug development for severe asthma: what are the metrics?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Drug development for severe asthma: what are the metrics?
@ast
Drug development for severe asthma: what are the metrics?
@en
type
label
Drug development for severe asthma: what are the metrics?
@ast
Drug development for severe asthma: what are the metrics?
@en
prefLabel
Drug development for severe asthma: what are the metrics?
@ast
Drug development for severe asthma: what are the metrics?
@en
P2093
P2860
P1476
Drug development for severe asthma: what are the metrics?
@en
P2093
Cynthia B Robinson
Joanne Leonard
Reynold A Panettieri
P2860
P304
P356
10.1016/J.PHARMTHERA.2012.05.005
P577
2012-05-22T00:00:00Z